PRAX: FDA Grants Breakthrough Therapy
Praxis Precision Medicines receives Breakthrough Therapy designation from FDA for Elsunersen to treat seizures associated with SCN2A development and epileptic encephalopathy
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.